220 related articles for article (PubMed ID: 33051130)
1. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.
Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO
Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130
[TBL] [Abstract][Full Text] [Related]
2. A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing.
Koppes EA; Redel BK; Johnson MA; Skvorak KJ; Ghaloul-Gonzalez L; Yates ME; Lewis DW; Gollin SM; Wu YL; Christ SE; Yerle M; Leshinski A; Spate LD; Benne JA; Murphy SL; Samuel MS; Walters EM; Hansen SA; Wells KD; Lichter-Konecki U; Wagner RA; Newsome JT; Dobrowolski SF; Vockley J; Prather RS; Nicholls RD
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 33055427
[TBL] [Abstract][Full Text] [Related]
3. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.
Villiger L; Grisch-Chan HM; Lindsay H; Ringnalda F; Pogliano CB; Allegri G; Fingerhut R; Häberle J; Matos J; Robinson MD; Thöny B; Schwank G
Nat Med; 2018 Oct; 24(10):1519-1525. PubMed ID: 30297904
[TBL] [Abstract][Full Text] [Related]
4. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
5. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
6. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
Hamman KJ; Winn SR; Harding CO
Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
[TBL] [Abstract][Full Text] [Related]
7. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B
Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925
[TBL] [Abstract][Full Text] [Related]
8. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
9. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
Ding Z; Georgiev P; Thöny B
Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
[TBL] [Abstract][Full Text] [Related]
10. Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria.
Martínez-Pizarro A; Álvarez M; Dembic M; Lindegaard CA; Castro M; Richard E; Andresen BS; Desviat LR
Nucleic Acid Ther; 2024; 34(3):134-142. PubMed ID: 38591802
[TBL] [Abstract][Full Text] [Related]
11. A bone mineralization defect in the Pah
Dobrowolski SF; Tourkova IL; Robinson LJ; Secunda C; Spridik K; Blair HC
Mol Genet Metab; 2018 Nov; 125(3):193-199. PubMed ID: 30201326
[TBL] [Abstract][Full Text] [Related]
12. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector.
Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A
J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAH(enu2) mouse model of phenylketonuria.
Dobrowolski SF; Lyons-Weiler J; Spridik K; Vockley J; Skvorak K; Biery A
Mol Genet Metab; 2016 Sep; 119(1-2):1-7. PubMed ID: 26822703
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 generated knockout mice lacking phenylalanine hydroxylase protein as a novel preclinical model for human phenylketonuria.
Singh K; Cornell CS; Jackson R; Kabiri M; Phipps M; Desai M; Fogle R; Ying X; Anarat-Cappillino G; Geller S; Johnson J; Roberts E; Malley K; Devlin T; DeRiso M; Berthelette P; Zhang YV; Ryan S; Rao S; Thurberg BL; Bangari DS; Kyostio-Moore S
Sci Rep; 2021 Mar; 11(1):7254. PubMed ID: 33790381
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.
Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL
Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Acta Paediatr Suppl; 1994 Dec; 407():124-9. PubMed ID: 7766948
[TBL] [Abstract][Full Text] [Related]
17. Gene Editing Successfully Corrects 2 Amino Acid Disorders: In 2 preclinical studies using CRISPR-mediated gene editing, phenylketonuria and hereditary tyrosinemia type 1 were corrected.
Am J Med Genet A; 2019 Jan; 179(1):5-6. PubMed ID: 30681273
[No Abstract] [Full Text] [Related]
18. State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.
Grisch-Chan HM; Schwank G; Harding CO; Thöny B
Hum Gene Ther; 2019 Oct; 30(10):1274-1283. PubMed ID: 31364419
[TBL] [Abstract][Full Text] [Related]
19. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy.
Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627
[TBL] [Abstract][Full Text] [Related]
20. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model.
Kaiser RA; Weber ND; Trigueros-Motos L; Allen KL; Martinez M; Cao W; VanLith CJ; Hillin LG; Douar A; González-Aseguinolaza G; Aldabe R; Lillegard JB
J Inherit Metab Dis; 2021 Nov; 44(6):1369-1381. PubMed ID: 33896013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
